BofA moves to No Rating from Buy on Paragon 28 (FNA) as the firm believes the stock is no longer trading on its fundamentals after Zimmer Biomet (ZBH) agreed to acquire the company for $13 in cash per share plus up $1 per share in a contingent value right.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FNA:
- Treace Medical ‘a rarer asset’ after Zimmer buys Paragon 28, says Lake Street
- Paragon 28 downgraded to Market Perform from Outperform at William Blair
- M&A News: Zimmer Biomet to Buy Paragon 28 in a $1.1B Deal
- Zimmer Biomet to acquire Paragon 28 for $13.00 per share in cash upfront
- Paragon 28 falls -9.5%